Hanall Biopharma Free Cash Flow Generation Index
Hanall Biopharma free cash flow generation index. Hanall Biopharma (009420) has a Free Cash Flow Generation Index of 0.55x as of September 2025. Free cash flow of ₩4.07 Billion represents 1% of operating cash flow (₩7.34 Billion). Check asset resilience ratio of Hanall Biopharma to evaluate the company's liquid asset resilience ratio.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
Free Cash Flow Generation Index of Hanall Biopharma (2011–2024)
Free cash flow generation index of Hanall Biopharma from 2011 to 2024. Historical FCF Generation Index trend for Hanall Biopharma across 10 annual periods. Explore Hanall Biopharma (009420) reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
Hanall Biopharma Free Cash Flow Generation Index by Year (2011–2024)
Hanall Biopharma free cash flow generation index by year from 2011 to 2024. Year-by-year Free Cash Flow Generation Index for Hanall Biopharma. For the full cash flow conversion analysis, see 009420 cash flow conversion.
| Year | FCG Index | Free Cash Flow (KRW) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2024 | -1.46x | ₩-13.71 Billion | ₩9.36 Billion | ₩23.07 Billion | ▼ -312.3% |
| 2023 | 0.69x | ₩20.45 Billion | ₩29.64 Billion | ₩9.20 Billion | ▼ -0.8% |
| 2022 | 0.70x | ₩17.53 Billion | ₩25.20 Billion | ₩2.83 Billion | ▲ +107.2% |
| 2021 | -9.72x | ₩-8.16 Billion | ₩839.87 Million | ₩4.61 Billion | ▼ -39.8% |
| 2020 | -6.95x | ₩-6.46 Billion | ₩929.29 Million | ₩2.56 Billion | ▼ -1266.2% |
| 2019 | 0.60x | ₩12.22 Billion | ₩20.49 Billion | ₩2.12 Billion | ▼ -37.1% |
| 2017 | 0.95x | ₩39.93 Billion | ₩42.14 Billion | ₩1.73 Billion | ▼ -53.1% |
| 2016 | 2.02x | ₩7.98 Billion | ₩3.95 Billion | ₩4.03 Billion | ▲ +1.3% |
| 2012 | 1.99x | ₩4.38 Billion | ₩2.20 Billion | ₩2.18 Billion | ▲ +88.6% |
| 2011 | 1.06x | ₩7.84 Billion | ₩7.41 Billion | ₩426.70 Million | — |